What topics does this cannabis study cover?

This study covers research on: Mental Health, Neuroprotection.

Where was this research published?

Published in Clinical therapeutics on May 21, 2026.

Retinal changes may signal psychosis risk in early cannabis users

Q: What did this research study find?

This preliminary study examines potential **retinal biomarkers** that may indicate early risk for schizophrenia in cannabis users, particularly those who start before age 16. Researchers used innovative virtual reality-based frequency doubling technology (*IMMAD-FDT*) to measure contrast sensitivity

Early-Onset Cannabis Use, Retinal Biomarkers, and Risk for Schizophrenia Preliminary Study.

Clinical therapeutics • May 21, 2026 • Moderately Relevant

🤖

AI Summary

This preliminary study examines potential retinal biomarkers that may indicate early risk for schizophrenia in cannabis users, particularly those who start before age 16. Researchers used innovative virtual reality-based frequency doubling technology (IMMAD-FDT) to measure contrast sensitivity in the visual system, which is controlled by the magnocellular visual pathway and intrinsically photosensitive retinal ganglion cells. Of the six participants (12 eyes) studied, nine eyes showed abnormal contrast sensitivity compared to normative data at baseline, suggesting potential retinal dysfunction even when not acutely intoxicated.

The research highlights a critical connection between early cannabis initiation and visual system changes that mirror those observed in schizophrenia patients. Both conditions show similar patterns of visual dysfunction, including reduced low-frequency contrast sensitivity, thinning of the retinal nerve fiber layer, and damage to retinal ganglion cells. These structural and functional changes in the retina are also linked to impaired facial emotion recognition, a core symptom of social cognitive dysfunction in schizophrenia—suggesting the retina may serve as a non-invasive window into neural health.

While this is a small preliminary study, it points toward a promising direction for identifying early warning signs of psychotic risk in cannabis users. Future research combining IMMAD-FDT technology with optical coherence tomography imaging could establish retinal biomarkers for early risk stratification, allowing clinicians to identify vulnerable adolescents and develop preventative interventions. The findings underscore the importance of delaying cannabis use until the brain fully develops and demonstrate how eye-based testing could become a practical tool for assessing psychotic risk in high-risk populations.

📄 Original Abstract

Cannabis remains one of the most commonly used psychoactive substances among adolescents, with increasing prevalence of daily use during formative neurodevelopmental years. This preliminary study looks at changes in low spatial frequency contrast sensitivity perception using frequency doubling virtual reality technology (IMMAD-FDT). Early initiation of cannabis use-particularly before age 16-has been consistently linked to an elevated risk for schizophrenia and related psychotic disorders. The retina, as an extension of the central nervous system, offers a unique, non-invasive window into neural structure and function, with changes potentially detectable through contrast sensitivity chart testing, frequency doubling virtual visual field testing and optical coherence tomography structural imaging (OCT). This project looked at six participants data obtained under an Advarra Institutional Review Board Approved protocol; Digital Marker of Marijuana Intoxication: Measure of Dysfunctional Retinal Ganglion Cell Response (Pro00038518). The project was funded through the National Institute of Health; Marijuana Intoxication: Roadside Tool for Law Enforcement to Measure Impaired Peripheral Vision 15PNIJ-22-GG-04417-RESS. The data of interest were from the IMMAD-FDT. We reviewed dosed and undosed data relative to the IMMAD-FDT normative database. IMMAD-FDT measures contrast sensitivity at low spatial frequencies using temporally modulated striped square targets. The targets are displayed in a commercially available virtually reality headset equipped with eye tracking, allowing for precise measurement of threshold contrast sensitivity in decibels. This approach is particularly sensitive to dysfunction in the magnocellular visual pathway and intrinsically photosensitive retinal ganglion cells (ipRGCs). Of the six participants; 12 eyes, nine eyes were considered abnormal relative to the normative data base, at an undosed baseline. Previous work demonstrates overlapping patterns of visual dysfunction and retinal remodeling in both schizophrenia and chronic cannabis use, including deficits in low spatial frequency contrast sensitivity, thinning or changes of the retinal nerve fiber layer, and alterations in retinal ganglion cell integrity. These functional and structural changes are also associated with impaired facial emotion recognition, a hallmark of social cognitive dysfunction in schizophrenia. This paper synthesizes current evidence and describes further investigation using virtual reality-based IMMAD-FDT and discusses how the preliminary findings may relate to future more controlled studies that would include OCT imaging to identify early retinal biomarkers in abstinent cannabis users, categorized by age of onset and frequency of use. Future research would relate the functional and structural findings with additional tests of emotion cognition/facial recognition. Findings could inform early risk stratification and preventative interventions for psychosis.